glp-1

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain. According to Gill, while Eli Lilly And Co's (NYSE:LLY) direct-to-consumer push is...

Eli Lilly and Co. (NYSE:LLY) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Chart created using Benzinga Pro Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot...

Novo Nordisk AS (NYSE:NVO) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours. The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co’s (NYSE:LLY), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs shortage list. What Happened: The FDA said in a statement late...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking’s obesity drug...

GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted...

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga. “Our view is that in the long term, this is not a two-horse race...

Eli Lilly And Co (NYSE:LLY) might see a significant boost due to supply issues at competitor Novo Nordisk A/S (NYSE:NVO), according to Reddit user serkankster. $LLY up potential byu/serkankster instocks It was noted that Eli Lilly’s weight loss drug Zepbound resolved previous supply...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most...

Goldman Sachs analysts are identifying a substantial opportunity in the manufacturing sector for new obesity therapeutics as demand escalates for these treatments. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting...

Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey’s upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs. What Happened: Black, a well-known investor, took to X,...

Bank of America’s equity strategist Savita Subramanian on Sunday revised the year-end target for the S&P 500 to 5,400, up from the previous target of 5,000, signaling a modest 5% upside potential. Despite a more positive outlook, there’s an acknowledgment of the market’s...